FDA Clears New Interventional X-Ray Platform from United Imaging
Employing intelligent robotics and enhanced low-dose image quality, the uAngio AVIVA X-ray system also offers hands-free image review and movement.
The Food and Drug Administration (FDA) has granted 510(k) clearance for the uAngio AVIVA interventional radiology X-ray system, which is reportedly the first interventional platform to offer a voice-assist component.
The intelligent voice assist enables hands-free image review and movement for interventional radiologists, according to United Imaging, the manufacturer of uAngio AVIVA.
The newly FDA-cleared uAngio AVIVA interventional radiology system is reportedly the first to offer intelligent voice assist to enable hands-free image review and movement, according to United Imaging, the manufacturer of uAngio AVIVA. (Image courtesy of United Imaging.)
United Imaging said other key attributes of the uAngio AVIVA platform include easy tableside access and flexibility with the 8-axis ceiling-mounted robotic system as well as proprietary artificial intelligence (AI) algorithms that facilitate quality low-dose imaging for a variety of interventional procedures.
“It is exciting to continue bringing industry firsts to healthcare. And, as with all the technology we offer, we are bringing it to market with All-In Configurations, Software Upgrades for Life™, and the other groundbreaking business models we've invented to make it simpler and more cost transparent for healthcare providers to purchase,” noted Jeffrey M. Bundy, Ph.D., the CEO of United Imaging Healthcare North America.
Can Emerging AI Software Offer Detection of CAD on CCTA on Par with Radiologists?
May 14th 2025In a study involving over 1,000 patients who had coronary computed tomography angiography (CCTA) exams, AI software demonstrated a 90 percent AUC for assessments of cases > CAD-RADS 3 and 4A and had a 98 percent NPV for cases > CAD-RADS 4A.
Mammography Study Compares False Positives Between AI and Radiologists in DBT Screening
May 8th 2025For DBT breast cancer screening, 47 percent of radiologist-only flagged false positives involved mass presentations whereas 40 percent of AI-only flagged false positive cases involved benign calcifications, according to research presented at the recent American Roentgen Ray Society (ARRS) conference.
